Cada estudo citado no palco, reunido para você.

1. Fagron Brasil. Pré-TRH Test.

   Linkbr.fagron.com/products/pre-trh-test/

2. The North American Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767-794.

   PubMed35797481

3. Davis SR et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019.

   PubMed31474158

4. Parish SJ et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for Systemic Testosterone for HSDD in Women. J Womens Health. 2021.

   PubMed33797277

5. Haiman CA et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007;67:1893-1897.

   DOI10.1158/0008-5472.CAN-06-4123

6. Sowers MR et al. CYP1A1 and CYP1B1 polymorphisms and their association with estradiol and estrogen metabolites. Am J Med. 2006.

   DOI10.1016/j.amjmed.2006.07.006

7. Crandall CJ et al. Genetic Variation and Hot Flashes: A Systematic Review. J Clin Endocrinol Metab. 2020;105:e4907-e4957.

   DOI10.1210/clinem/dgaa536

8. Dawling S et al. COMT-mediated metabolism of catechol estrogens. Cancer Res. 2001;61:6716-6722.

   PubMed11559542

9. Moyer AM et al. Influence of SULT1A1 genetic variation on age at menopause, estrogen levels, and response to hormone therapy. Menopause. 2016;23:863-869.

   DOI10.1097/GME.0000000000000648

10. Bastaki M et al. Genotype-activity relationship for manganese superoxide dismutase, glutathione peroxidase 1 and catalase in humans. Pharmacogenet Genomics. 2006;16:279-286.

    DOI10.1097/01.fpc.0000199498.08725.9c

11. Ramos PM et al. Female-pattern hair loss: therapeutic update. An Bras Dermatol. 2023.

    DOI10.1016/j.abd.2022.09.006

12. Aleissa M. The Efficacy and Safety of Oral Spironolactone in Female Pattern Hair Loss. Cureus. 2023.

    PubMed37719557

13. Price VH et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000.

    PubMed11050579

14. Kim KH et al. Efficacy of Finasteride in Female Pattern Hair Loss: a meta-analysis. Ann Dermatol. 2021.

    PubMed34079198

15. Gao S et al. Developing nutritional component chrysin as a therapeutic agent. Biomed Pharmacother. 2021.

    DOI10.1016/j.biopha.2021.112080

16. Park MH et al. Inhibitory effect of Rhus verniciflua extract on human aromatase activity. Bioorg Med Chem Lett. 2014.

    PubMed24630560

Voltar ao índice

1. OLIVEIRA, C. R. et al. Anti-Inflammatory Activity of Miodesin®: Modulation of Inflammatory Markers and Epigenetic Evidence. Oxidative Medicine and Cellular Longevity. Hindawi. Vol. 2020, Art. ID 6874260, 11 pg.

   DOI10.1155/2020/6874260

2. BMC Complementary Medicine and Therapies volume 24, Article number: 405 2024

   Linklink.springer.com/journal/12906

3. Suppression of lipopolysaccharide-stimulated cytokine/chemokine production in skin cells by sandalwood oils and purified α-santalol and β-santalol

   DOI10.1002/ptr.5080

4. A Novel Extract of Fenugreek Husk (FenuSMART™) Alleviates Postmenopausal Symptoms and Helps to Establish the Hormonal Balance: A Randomized, Double-Blind, Placebo-Controlled Study

   DOI10.1002/ptr.5680

5. Efficacy of a novel extract of fenugreek seeds in alleviating vasomotor symptoms and depression in perimenopausal women: A randomized, double-blinded, placebo-controlled study

   DOI10.1111/jfbc.13507

6. Phytoestrogenic effect of fenugreek seed extract helps in ameliorating the leg pain and vasomotor symptoms in postmenopausal women: A randomized, double-blinded, placebo-controlled study

   DOI10.1016/j.phanu.2020.100209

7. Safety and influence of a novel extract of fenugreek on healthy young women: a randomized, double-blinded, placebo-controlled study

   DOI10.1186/s40816-021-00296-y

8. Differential effects of soybean and fenugreek extracts on the growth of MCF-7 cells

   DOI10.1016/j.cbi.2007.07.011

9. A Standardized Asparagus Racemosus Root Extract Improves Hormonal Balance and Menstrual Health and Reduces Vasomotor Symptoms in Perimenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study

   DOI10.1080/27697061.2025.2510474

10. what is the range of antimullerian healthy levels? - SciSpace Literature Review

    Sem DOI ou PMID na referência original.

11. Pharmaceuticals 2022, 15(3), 278;

    DOI10.3390/ph15030278

12. Potential phytoestrogen alternatives exert cardio-protective mechanisms via estrogen receptors

    DOI10.1051/bmdcn/2017070204

13. Effects of fenugreek supplementation on the components of metabolic syndrome: A systematic review and dose-response meta-analysis of randomized clinical trials

    DOI10.1016/j.phrs.2022.106594

Voltar ao índice

1. Rossouw JR, Anderson GL. Prentice RL, et al. Risks and benefits on estrogen plus progestin in healthy postmenopausal women: principal results From the Women Health Initiative randomized controlled trial. JAMA. 2002:288(3)

   DOI10.1001/jama.288.3.321

2. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. O coração do mundo. Glob Heart. 2024;19(1):11.

   DOI10.5334/gh.1288

3. DOI: 10.5334/gh.1288

   DOI10.1056/NEJMoa2609059

4. Borja Ibanez, MD, PHD,a,b,c, * Antonio Fernández-Ortiz, MD, PHD,a,c,d, * Leticia Fernández-Friera, MD, PHD,a,c,e Inés García-Lunar, MD, PHD,a,c,f Vicente Andrés, PHD,a,c Valentín Fuster, MD, PHDa,g

   DOI10.1016/j.jacc.2021.05.011

Voltar ao índice

1. Burkman RT, Collins JA, Greene RA. Current perspectives on benefits and risks of hormone replacement therapy. Am J Obstet Gynecol. 2001;185(2 Suppl):S13-S23.

   DOI10.1067/mob.2001.117414

2. Gersh F et al. Estrogen and cardiovascular disease. Prog Cardiovasc Dis. 2024;84:60-67.

   DOI10.1016/j.pcad.2024.01.015PubMed38272338

3. Mounier-Vehier C et al. Klotz communications 2021: Heart and Hormones. Women's cardiovascular risk before and after menopause: A red alert for heart attack! Ann Endocrinol (Paris). 2021;82(3-4):134.

   DOI10.1016/j.ando.2020.03.006

4. NAMS Practice Pearl. Hypertension in menopausal women: the effect and role of estrogen. Menopause. 2019;26(4):428-430.

   DOI10.1097/GME.0000000000001304

5. Ryczkowska K et al. Menopause and women's cardiovascular health: is it really an obvious relationship? Arch Med Sci. 2023;19(2):458-466.

   DOI10.5114/aoms/157308

6. Boardman HMP et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015.

   DOI10.1002/14651858.CD002229.pub4

7. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.

   DOI10.1097/GME.0000000000002028PubMed35797481

8. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3-63.

   DOI10.1080/13697130500148875

9. Consenso Brasileiro de Terapêutica Hormonal do Climatério 2024.

   Sem DOI ou PMID na referência original.

10. Benedetto C, Gulati M, Khadilkar SS, et al. Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper. Int J Gynecol Obstet. 2026.

    DOI10.1002/ijgo.71356

Voltar ao índice

1. Furness S et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012.

   DOI10.1002/14651858.CD000402.pub4

2. Piette P. The history of natural progesterone, the never-ending story. Climacteric. 2018;21(4):308-314.

   DOI10.1080/13697137.2018.1462792

3. Hamoda H; British Menopause Society. British Menopause Society tools for clinicians: progestogens and endometrial protection. Post Reprod Health. 2022;28(1):40-46.

   DOI10.1177/20533691211058030

4. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199-208.

   DOI10.1001/jama.1995.03520270033028

5. White WB et al. Effects of a new hormone therapy, drospirenone and 17-β-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48(2):246-253.

   DOI10.1161/01.HYP.0000232179.60442.84

6. Caufriez A et al. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab. 2011;96(4):E614-E623.

   DOI10.1210/jc.2010-2558

7. Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018;21(4):346-354.

   DOI10.1080/13697137.2018.1455657

8. Sturdee DW et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011;14(3):302-320.

   DOI10.3109/13697137.2011.570590

9. Prentice A et al., Cochrane 2000.

   Sem DOI ou PMID na referência original.

10. Weisberg et al., 2005.

    Sem DOI ou PMID na referência original.

11. Brache et al., 2015.

    Sem DOI ou PMID na referência original.

12. Silvin et al., 2005.

    Sem DOI ou PMID na referência original.

13. Ylänen et al., 2003.

    Sem DOI ou PMID na referência original.

14. ANDERSON, G. L. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA, v. 291, n. 14, p. 1701-1712, 2004.

    DOI10.1001/jama.291.14.1701

15. BROWN, J.; KIVES, S.; AKHTAR, M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database of Systematic Reviews, n. 3, art. CD002122, 2012.

    DOI10.1002/14651858.CD002122.pub2

16. CANONICO, M. et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, v. 115, n. 7, p. 840-845, 2007.

    DOI10.1161/CIRCULATIONAHA.106.642280

17. CHENE, G. et al. The role of progestin subdermal implant in the management of adenomyosis: a systematic review. The European Journal of Contraception & Reproductive Health Care, v. 29, n. 2, p. 61-68, 2024.

    DOI10.1080/13625187.2024.2314298

18. CICINELLI, E. et al. Direct transport of progesterone from vagina to uterus. Obstetrics & Gynecology, v. 95, n. 3, p. 403-406, 2000.

    DOI10.1016/S0029-7844(99)00542-6

19. COUTINHO, E. M.; AZADIAN-BOULANGER, G. Treatment of endometriosis by vaginal administration of gestrinone. Fertility and Sterility, v. 49, n. 3, p. 418-422, 1988.

    DOI10.1016/S0015-0282(16)59765-9

20. DEPYPERE, H.; INKI, P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric, v. 18, n. 4, p. 470-482, 2015.

    DOI10.3109/13697137.2014.991302

21. FOURNIER, A.; BERRINO, F.; CLAVEL-CHAPELON, F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment, v. 107, n. 1, p. 103-111, 2008.

    DOI10.1007/s10549-007-9523-x

22. KUMAR, N.; KOIDE, S. S.; TSONG, Y.; SUNDARAM, K. Nestorone: a progestin with a unique pharmacological profile. Steroids, v. 65, n. 10-11, p. 629-636, 2000.

    DOI10.1016/S0039-128X(00)00119-7

23. MALAVASI, A. et al. Pharmacokinetic analysis of 25 mg estradiol subcutaneous bioabsorbable implant in postmenopausal women (CLARA STUDY). Menopause, v. 33, n. 4, p. 425-435, 2026.

    DOI10.1097/GME.0000000000002687

24. MALAVASI, A. et al. Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain. Annals of Medicine, v. 57, n. 1, art. 2527352, 2025.

    DOI10.1080/07853890.2025.2527352

25. NORTH AMERICAN MENOPAUSE SOCIETY. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, v. 29, n. 7, p. 767-794, 2022.

    DOI10.1097/GME.0000000000002028

26. OLIVEIRA, A. L. M. de et al. Gestrinone subdermal bioabsorbable implant for the treatment of endometriosis-associated pelvic pain: a phase II, safety randomised clinical trial. SSRN, 2026. Preprint.

    DOI10.2139/ssrn.6509072

27. PEPI TRIAL WRITING GROUP. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, v. 275, n. 5, p. 370-375, 1996.

    DOI10.1001/jama.1996.03530290040035

28. RENKE, G.; ANTUNES, M.; SAKATA, R.; TOSTES, F. Effects, doses, and applicability of gestrinone in estrogen-dependent conditions and post-menopausal women. Pharmaceuticals, v. 17, n. 9, art. 1248, 2024.

    DOI10.3390/ph17091248

29. RENKE, G. et al. Clinical approaches to Nestorone subdermal implant therapy in women's health. Biomedicines, v. 11, n. 9, art. 2586, 2023.

    DOI10.3390/biomedicines11092586

30. ROSSOUW, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, v. 288, n. 3, p. 321-333, 2002.

    DOI10.1001/jama.288.3.321

31. SCHINDLER, A. E. et al. Classification and pharmacology of progestins. Maturitas, v. 46, supl. 1, p. S7-S16, 2003.

    DOI10.1016/j.maturitas.2003.09.014

32. STANCZYK, F. Z.; HAPGOOD, J. P.; WINER, S.; MISHELL JR., D. R. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine Reviews, v. 34, n. 2, p. 171-208, 2013.

    DOI10.1210/er.2012-1008

33. STUTE, P.; NEULEN, J.; WILDT, L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric, v. 19, n. 4, p. 316-328, 2016.

    DOI10.1080/13697137.2016.1187123

34. WREN, B. G.; CHAMPION, S. M.; WILLETTS, K.; MANGA, R. Z.; EDEN, J. A. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause, v. 10, n. 1, p. 13-18, 2003.

    DOI10.1097/00042192-200310010-00004

Voltar ao índice

1. Testosterone and pre-androgens by age and menopausal stage at midlife: findings from a cross-sectional study

   DOI10.1016/j.ebiom.2025.105972

2. Global Consensus Position Statement on the Use of Testosterone Therapy for Women

   DOI10.1080/13697137.2019.1637079

3. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data

   DOI10.1016/S2213-8587(19)30189-5

4. Testosterone therapy for female sexual dysfunction: a systematic review of the literature demonstrating outcomes in premenopausal and postmenopausal women

   DOI10.1093/jsxmed/qdag206

5. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen

   DOI10.1056/NEJMoa0707302

6. Effect of trandermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study

   DOI10.1007/s00737-024-01513-6

7. Testosterone dose-response relationship in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial

   DOI10.1097/GME.0000000000000093PubMed24281237

8. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality

   DOI10.1016/0378-5122(94)00898-h

9. "Can nandrolone add to the effect of hormonal replacement therapy in postmenopausal osteoporosis?"

   DOI10.1016/0169-6009(92)90811-q

10. Double-Blind Placebo-Controlled Trial of Treatment of Osteoporosis with the Anabolic Nandrolone Decanoate

    DOI10.1007/BF01621912

11. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in woman with established post-menopausal osteoporosis: a double-blind placebo-controlled study

    DOI10.1016/0378-5122(89)90210-7

12. The Effect of Nandrolone Decanoate on Bone Mineral Density, Muscle Mass, and Hemoglobin Levels in Elderly Women With Osteoporosis: A Double-Blind Randomized, Placebo-Controlled Clinical Trial

    DOI10.1093/gerona/60.5.648

13. Effects of nandrolone decanoate on bone mass in established osteoporosis

    DOI10.1016/0378-5122(93)90049-n

14. Effect of nandrolone decanoate and 1-α-Hydroxy-calciferol on patient with vertebral osteoporotic collapse. A double-blind clinical trial | George P. Lyritis, Costa Androulakis, Basil Magiasis, Zacharenia Charalambaki, Nikos Tsakalakos

    DOI10.1016/s0169-6009(08)80194-8

15. Course of Bone Mass During and after hormonal replacement therapy with withot addition of nandrolone decanoate

    DOI10.1002/jbmr.5650090217

16. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis

    DOI10.1007/BF01623456

17. Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine

    DOI10.1007/BF00297289

18. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?

    DOI10.1016/0169-6009(89)90025-1

19. Oxandrolone Augmentation of Resistance Training in Older Women: A Randomized Trial

    DOI10.1249/MSS.0000000000000690

20. Androgen Therapy Induces Muscle Protein Anabolism In Older Women

    DOI10.1210/jc.2006-0588

21. Global Consensus Position Statement on the Use of Testosterone Therapy for Women

    DOI10.1016/j.jsxm.2019.07.012

22. Sexual Dysfunction in Women

    DOI10.1056/NEJMcp2313307

23. Measuring serum testosterone in women

    DOI10.1016/S2213-8587(24)00134-7

24. Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG)

    DOI10.1080/13697137.2025.2548805

25. Associations between testosterone and pre-androgens and sexual function; findings from the Australian Women's Midlife Years Study

    DOI10.1016/j.fertnstert.2026.05.156

26. The association between testosterone and depression in postmenopausal women: A systematic review of observational studies

    DOI10.1016/j.maturitas.2022.11.001

27. Endogenous testosterone concentrations and muscle mass, strength and performance in women, a systematic review of observational studies

    DOI10.1111/cen.14874

28. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause. 2003;10(5):390-398.

    DOI10.1097/01.GME.0000060256.03945.20

29. Davis SR et al. Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clin Endocrinol. 2014;81(4):621-628.

    DOI10.1111/cen.12459

30. Parish SJ et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867.

    DOI10.1016/j.jsxm.2020.10.009

Voltar ao índice

1. Gallez A et al., Estetrol and Mammary Gland: Friends or Foes? J Mammary Gland Biol Neoplasia. 2021

   DOI10.1007/s10911-021-09497-0

2. Itou J. Estetrol prevents estradiol-induced precancerous cell proliferation in mice. Biochem Biophys Res Commun. 2025

   DOI10.1016/j.bbrc.2025.152908

3. Coelingh Bennink HJT et al., Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model. Climacteric. 2008

   DOI10.1080/13697130802040325

4. Singer CF et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014

   DOI10.1093/carcin/bgu144

5. Schmidt M et al. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol. 2021

   DOI10.1007/s00432-020-03472-8

Voltar ao índice

1. Prevalence of osteosarcopenia in postmenopausal women: systematic review and meta-analysis. 2026.

   DOI10.1007/s40618-026-02900-9PubMed42258024

2. LeBoff MS et al. Osteoporos Int. 2022;33:2049–2102.

   DOI10.1007/s00198-021-05900-y

3. Cruz-Jentoft AJ et al. Age Ageing. 2019;48:16–31.

   DOI10.1093/ageing/afy169

4. European Society of Endocrinology Clinical Practice Guideline for Menopause and Perimenopause. Eur J Endocrinol. 2025;193:G49–G81.

   DOI10.1093/ejendo/lvaf206

5. Campbell et al. Muscle and the Menopause. Obstet Gynaecol. 2026.

   DOI10.1111/tog.70046

6. Davis SR et al. Global Consensus Position Statement on Testosterone Therapy for Women. JCEM. 2019;104:4660–4666.

   DOI10.1210/jc.2019-01603

7. Zanker J et al. Consensus guidelines for sarcopenia. J Cachexia Sarcopenia Muscle. 2023;14:142–156.

   DOI10.1002/jcsm.13115

8. LeBoff MS et al. Osteoporos Int. 2022;33:2049–2102. Cruz-Jentoft AJ et al. Age Ageing. 2019;48:16–31. ISCD. Official Adult Positions 2023.

   Linkiscd.org/official-positions-2023/

9. NOGG. Clinical Guideline. Updated 2024.

   Linkwww.nogg.org.uk/full-guideline

10. Effectiveness of exercise in postmenopausal women with sarcopenia. Front Public Health. 2026.

    DOI10.3389/fpubh.2026.1758325

11. Cui M et al. Chinese expert consensus on sarcopenia. Aging Med. 2023.

    DOI10.1002/agm2.12245

12. BHOF. Calcium and Vitamin D.

    Linkbonehealthandosteoporosis.org

13. hilibeck PD et al. Open Access J Sports Med. 2017;8:213–226.

    DOI10.2147/OAJSM.S123529

14. Cauley JA et al. WHI. JAMA. 2003;290:1729–1738.

    DOI10.1001/jama.290.13.1729

15. Javed AA et al. JAMA Netw Open. 2019;2:e1910154.

    DOI10.1001/jamanetworkopen.2019.10154

16. Javed AA et al. Menopause. 2020;27:827–835.

    Linkpubmed.ncbi.nlm.nih.gov/32187131/

17. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995;21(3):227-236.

    DOI10.1016/0378-5122(94)00898-HPubMed7616872

18. avis SR, Walker KZ, Strauss BJ. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women. Menopause. 2000;7(6):395-401.

    DOI10.1097/00042192-200011000-00005PubMed11127762

19. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab. 2002;87(4):1509-1516.

    DOI10.1210/jcem.87.4.8362PubMed11932273

20. Zang H, Carlström K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil Steril. 2006;86(1):136-144.

    DOI10.1016/j.fertnstert.2005.12.039PubMed16750207

21. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. J Reprod Med. 1999;44(12):1012-1020.

    PubMed10649811

22. Studd J, Savvas M, Watson N, Garnett T, Fogelman I, Cooper D. Am J Obstet Gynecol. 1990;163(5 Pt 1):1474-1479.

    DOI10.1016/0002-9378(90)90608-APubMed2240090

23. Savvas M, Studd JW, Norman S, Leather AT, Garnett TJ, Fogelman I. Br J Obstet Gynaecol. 1992;99(9):757-760.

    DOI10.1111/j.1471-0528.1992.tb13879.xPubMed1420016

24. Britto R, Araújo L, Barbosa I, Silva L, Rocha S, Valente AP. Gynecol Endocrinol. 2011;27(2):96-100.

    DOI10.3109/09513590.2010.489131PubMed20504104

25. | Mavros Y, O'Neill E, Connerty M, Bean JF, Broe K, Kiel DP, Maclean D, Taylor A, Fielding RA, Fiatarone Singh MA. Oxandrolone augmentation of resistance training in older women: a randomized trial. Med Sci Sports Exerc. 2015;47(11):2257-2267.

    DOI10.1249/MSS.0000000000000690PubMed25899102

26. Riggs BL, Jowsey J, Goldsmith RS, Kelly PJ, Hoffman DL, Arnaud CD. Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis. J Clin Invest. 1972;51(7):1659-1663.

    DOI10.1172/JCI106967PubMed4338118

27. Frisoli A Jr, Chaves PHM, Pinheiro MM, Szejnfeld VL. The effect of nandrolone decanoate on bone mineral density, muscle mass, and hemoglobin levels in elderly women with osteoporosis: a double-blind, randomized, placebo-controlled clinical trial. J Gerontol A Biol Sci Med Sci. 2005;60(5):648-653.

    DOI10.1093/gerona/60.5.648PubMed15972619

28. Camara LC, Ferreira MH, Junior NC. Nandrolone decanoate for postmenopausal osteoporosis: a systematic review and meta-analysis of randomized trials. Cureus. 2025;17(11):e98114.

    DOI10.7759/cureus.98114PubMed41477377

29. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. J Clin Endocrinol Metab. 2019;104(5):1595-1622.

    DOI10.1210/jc.2019-00221PubMed30907953

30. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. J Clin Endocrinol Metab. 2020;105(3):dgaa048.

    DOI10.1210/clinem/dgaa048PubMed32068863

31. LeBoff MS, Greenspan SL, Insogna KL, et al. Osteoporos Int. 2022;33(10):2049-2102.

    DOI10.1007/s00198-021-05900-yPubMed35478046

32. National Osteoporosis Guideline Group. Pharmacological treatment options. NOGG. Updated 2024.

    Linkwww.nogg.org.uk/full-guideline/section-6-pharmacological-treatment-options

33. International Osteoporosis Foundation. Epidemiology of osteoporosis and fragility fractures. Mortalidade por todas as causas no primeiro ano após fratura de quadril: até 20%. Disponível em: osteoporosis.foundation/facts-statistics. Mortalidade associada à fratura, não necessariamente causada exclusivamente por ela.

    Linkosteoporosis.foundation/facts-statistics

34. National Osteoporosis Guideline Group. Clinical Guideline for the Prevention and Treatment of Osteoporosis. NOGG. Updated 2024.

    Linkwww.nogg.org.uk

35. The North American Menopause Society. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794.

    DOI10.1097/GME.0000000000002028PubMed35797481

36. Watts NB et al., 1995.

    Sem DOI ou PMID na referência original.

37. Huang G et al., 2014.

    Sem DOI ou PMID na referência original.

38. Gennari C et al. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis. Maturitas. 1989.

    DOI10.1016/0378-5122(89)90210-7PubMed2687645

39. Johansen JS et al. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate? Bone Miner. 1989.

    DOI10.1016/0169-6009(89)90025-1PubMed2665884

40. Hassager C et al. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal. Maturitas. 1989;11(4):305-317.

    DOI10.1016/0378-5122(89)90027-3PubMed2693918

41. Flicker L et al. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporos Int. 1997.

    DOI10.1007/BF01623456PubMed9102059

42. Lyritis GP et al. Effect of nandrolone decanoate and 1-alpha-hydroxy-calciferol on patients with vertebral osteoporotic collapse. Bone Miner. 1994.

    DOI10.1016/S0169-6009(08)80194-8PubMed7696887

43. Dave B et al. Investigating the role of nandrolone decanoate in the management of osteosarcopenia in postmenopausal women: a prospective observational study. Cureus. 2025;17(5):e84726.

    DOI10.7759/cureus.84726PubMed40551939

Voltar ao índice

1. WHI (2002). Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002.

   DOI10.1001/jama.288.3.321

2. Million Women Study (2003). Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003.

   DOI10.1016/S0140-6736(03)14065-2

3. HABITS Trial (2004/2008). Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453-455. | Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. JNCI. 2008;100(7):475-482.

   DOI10.1016/S0140-6736(04)15493-7DOI10.1093/jnci/djn058

4. Lancet Collaborative Group (2019) / Santen et al., JCEM 2020. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk. Lancet. 2019;394(10204):1159-1168. | Santen RJ, Heitjan DF, Gompel A, et al. Underlying breast cancer risk and menopausal hormone therapy. J Clin Endocrinol Metab. 2020.

   DOI10.1016/S0140-6736(19)31709-XDOI10.1210/clinem/dgaa073

5. Chlebowski RT et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020.

   DOI10.1001/jama.2020.9482

6. Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269-275.

   DOI10.1007/s10549-021-06436-9

7. Coronado PJ, Gomez A, Iglesias E, et al. Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis. Menopause. 2024;31(3):234-242.

   DOI10.1097/GME.0000000000002317

8. Revisão Cochrane 2025. Bofill Rodriguez M, Yong LN, Mirkov S, Bekos C, Lethaby A, Farquhar C. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2025.

   DOI10.1002/14651858.CD004143.pub6

9. Consenso Delphi 2026. Glynne S, Simon J, Branson A, et al. Menopausal hormone therapy for breast cancer patients: what is the current evidence? Menopause. 2026;33(1):88-117.

   DOI10.1097/GME.0000000000002627

Voltar ao índice

1. Garmany A, Yamada S, Terzic A. Longevity leap: mind the healthspan gap. NPJ Regen Med. 2021;6:57.

   DOI10.1038/s41536-021-00169-5PubMed34556664

2. Chen CY et al. Gender differences in the relationships among neurosteroid serum levels, cognitive function, and quality of life. Neuropsychiatr Dis Treat. 2018;14:2389-2399.

   DOI10.2147/NDT.S176047

3. Javadi F et al. The effect of quercetin on inflammatory factors and clinical symptoms in women with rheumatoid arthritis: a double-blind, randomized controlled trial. J Am Coll Nutr. 2017;36(1):9-15.

   DOI10.1080/07315724.2016.1140093PubMed27710596

4. Aaseth J, Alexander J, Alehagen U. Coenzyme Q10 supplementation - In ageing and disease. Mech Ageing Dev. 2021;197:111521.

   DOI10.1016/j.mad.2021.111521

5. Int. J. Mol. Sci. 2019, 20.

   Sem DOI ou PMID na referência original.

Voltar ao índice

1. Donini et al. Clin Nutr. 2022.

   PubMed35227529

2. Nachit et al. Radiology. 2023.

   DOI10.1148/radiol.222008

3. Sattar et al. Lancet Diabetes Endocrinol. 2025.

   PubMed40318682

4. Tirzepatida agrupada, 52 semanas. Sattar et al. 2025.

   PubMed40318682

Voltar ao índice

1. Wilding et al. Composição corporal no STEP 1. J Endocr Soc. 2021;5(Suppl 1):A16–A17. / Look et al. Composição corporal no SURMOUNT-1. Diabetes Obes Metab. 2025;27:2720–2729.

   DOI10.1111/dom.16275

2. Wilding et al. Composição corporal no STEP 1. J Endocr Soc. 2021;5(Suppl 1):A16–A17. / Look et al. Composição corporal no SURMOUNT-1. Diabetes Obes Metab. 2025;27:2720–2729. doi:10.1111/dom.16275. / Cruz-Jentoft et al. Sarcopenia: revised European consensus. Age Ageing. 2019;48:16–31.

   DOI10.1148/radiol.222008

3. Cruz-Jentoft et al. Sarcopenia: revised European consensus. Age Ageing. 2019;48:16–31.

   DOI10.1093/ageing/afz046

4. Ng Tang Fui et al. Testosterone and hypocaloric diet. BMC Med. 2016;14:153.

   DOI10.1186/s12916-016-0700-9

5. Schroeder et al. Oxandrolone and durability of effects in older men. J Appl Physiol. 2004;96:1055–1062.

   DOI10.1152/japplphysiol.00808.2003

6. Pasiakos et al. Testosterone during severe energy deficit. EBioMedicine. 2019.

   DOI10.1016/j.ebiom.2019.07.059

7. Bhasin et al. Testosterone therapy in men with hypogonadism. JCEM. 2018;103:1715–1744.

   DOI10.1210/jc.2018-00229

8. Pasiakos et al. Testosterone during severe energy deficit. EBioMedicine. 2019.

   DOI10.1016/j.ebiom.2019.07.059

9. Bhasin et al. Testosterone therapy in men with hypogonadism. JCEM. 2018;103:1715–1744.

   DOI10.1210/jc.2018-00229

10. McFarland et al. Subcutaneous testosterone pharmacokinetics. J Endocr Soc. 2017;1:1095–1103.

    DOI10.1210/js.2017-00148

11. Johansen et al. Nandrolone and resistance training in hemodialysis. J Am Soc Nephrol. 2006;17:2307–2314.

    DOI10.1681/asn.2006010034

12. Passeri et al. Nandrolone and bone mass in established osteoporosis. Maturitas. 1993.

    DOI10.1016/0378-5122(93)90049-N

13. Goudreault & Massé. Urinary metabolites of methenolone acetate. J Steroid Biochem Mol Biol. 1990. PMID:2242348. NIH PubChem. Methenolone acetate. CID 252372.

    PubMed2242348

14. Oxandrin. Bula histórica norte-americana, janeiro de 2006. Indicações e segurança.

    DOI10.1016/0378-5122(93)90049-N

15. Davis et al. Global consensus on testosterone therapy for women. J Sex Med. 2019;16:1331–1337.

    DOI10.1016/j.jsxm.2019.07.012

16. Fontana et al. Two-year calorie restriction and IGF-1. Aging Cell. 2016;15:22–27.

    DOI10.1111/acel.12400

17. Molitch et al. Adult growth hormone deficiency. JCEM. 2011;96:1587–1609.

    DOI10.1210/jc.2011-0179

18. Heilbronn et al. Calorie restriction and metabolic adaptation. JAMA. 2006;295:1539–1548.

    DOI10.1001/jama.295.13.1539

19. Bhasin et al. Testosterone therapy in men with hypogonadism. JCEM. 2018;103:1715–1744.

    DOI10.1210/jc.2018-00229

20. Oxandrin. Bula histórica norte-americana, janeiro de 2006. Indicações e segurança.

    Sem DOI ou PMID na referência original.

21. Parish et al. ISSWSH guideline: systemic testosterone for HSDD. J Womens Health. 2021;30:474–491.

    DOI10.1089/jwh.2021.29037

22. Cruz-Jentoft et al. Sarcopenia: revised European consensus. Age Ageing. 2019;48:16–31. /

    DOI10.1093/ageing/afz046

23. Bhasin et al. Testosterone therapy in men with hypogonadism. JCEM. 2018;103:1715–1744

    DOI10.1210/jc.2018-00229

24. Davis et al. Global consensus on testosterone therapy for women. J Sex Med. 2019;16:1331–1337.

    DOI10.1016/j.jsxm.2019.07.012

25. Bhasin et al. Testosterone therapy in men with hypogonadism. JCEM. 2018;103:1715–1744. / Oxandrin. Bula histórica norte-americana, janeiro de 2006. Indicações e segurança. / Davis et al. Global consensus on testosterone therapy for women. J Sex Med. 2019;16:1331–1337. / Molitch et al. Adult growth hormone deficiency. JCEM. 2011;96:1587–1609.

    DOI10.1210/jc.2018-00229DOI10.1016/j.jsxm.2019.07.012

26. Jastreboff et al. Retatrutide for obesity: phase 2. N Engl J Med. 2023;389:514–526.

    DOI10.1056/nejmoa2301972

Voltar ao índice

1. Pasquali R et al. Eur J Endocrinol. 2020;182:G1–G32.

   DOI10.1530/EJE-19-0893PubMed31855556

Voltar ao índice

1. Busk-Cirera L et al. Effects of incretin-based therapies, diet and exercise interventions, and bariatric surgery on fat-free mass in adults with overweight or obesity: a systematic review and meta-analysis. Diabetes, Obesity & Metabolism. 2026.

   DOI10.1111/dom.71006PubMed42324178

2. Verreijen AM et al. Effect of a high protein diet and/or resistance exercise on the preservation of fat free mass during weight loss in overweight and obese older adults: a randomized controlled trial. Nutrition Journal. 2017;16(1):1-10.

   DOI10.1186/s12937-017-0229-6PubMed28166780

3. Kreider RB et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14(1):18.

   DOI10.1186/s12970-017-0173-zPubMed28615996

4. Desai et al., 2024. Metanálise de creatina com treinamento resistido em adultos com menos de 50 anos.

   Sem DOI ou PMID na referência original.

Voltar ao índice

1. ACP Living Clinical Guideline. Ann Intern Med. 2026.

   Sem DOI ou PMID na referência original.

2. Apovian CM et al. Endocr Pract. 2022 (AACE/ACE).

   Sem DOI ou PMID na referência original.

3. Wilding JPH et al. NEJM 2021 (STEP 1).

   DOI10.1056/NEJMoa2032183PubMed33567185

4. Jastreboff AM et al. NEJM 2022 (SURMOUNT-1).

   DOI10.1056/NEJMoa2206038PubMed35658024

5. Aronne LJ et al. NEJM 2025 (SURMOUNT-5).

   DOI10.1056/NEJMoa2416394PubMed40353578

6. Lincoff AM et al. NEJM 2023 (SELECT).

   DOI10.1056/NEJMoa2307563PubMed37952131

7. Wilding JP et al. Diabetes Obes Metab. 2022 (STEP 1 Extension).

   DOI10.1111/dom.14725PubMed35441470

8. Aronne LJ et al. JAMA 2024 (SURMOUNT-4).

   DOI10.1001/jama.2023.24945PubMed38078870

9. Berthoud HR et al. Cell Metab. 2021.

   Sem DOI ou PMID na referência original.

10. Morton GJ et al. Nat Rev Neurosci. 2014.

    DOI10.1038/nrn3745PubMed24840801

11. Sumithran P et al. NEJM 2011.

    DOI10.1056/NEJMoa1105816PubMed22029981

12. Tronieri JS et al. Metabolism. 2019 (liraglutida + fentermina).

    DOI10.1016/j.metabol.2019.03.005PubMed30902750

13. Acosta A et al. Obesity. 2021 (fenótipos).

    DOI10.1002/oby.23120PubMed33759389

14. Gadde KM et al. Lancet 2011 (fentermina/topiramato).

    DOI10.1016/S0140-6736(11)60205-5PubMed21481449

15. Greenway FL et al. Lancet 2010 (COR-I).

    DOI10.1016/S0140-6736(10)60888-4PubMed20673995

16. James WP et al. NEJM 2010 (SCOUT).

    DOI10.1056/NEJMoa1003114PubMed20818901

17. Clément K et al. Lancet Diabetes Endocrinol. 2020 (setmelanotida).

    DOI10.1016/S2213-8587(20)30364-8PubMed33137293

18. McElroy SL et al. Int J Eat Disord. 2016 (ensaios de lisdexanfetamina no transtorno de compulsão alimentar).

    Sem DOI ou PMID na referência original.

19. Cypess AM et al. Cell Metab. 2015.

    DOI10.1016/j.cmet.2014.12.009PubMed25565203

20. Müller MJ et al. Obes Rev. 2018.

    Sem DOI ou PMID na referência original.

Voltar ao índice

1. Argyrakopoulou G et al. Nutritional Deficiencies Before and After Bariatric Surgery: Prevention and Treatment. Curr Nutr Rep. 2022;11(2):95-101.

   DOI10.1007/s13668-022-00400-9PubMed35174473

2. Kumar R et al. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19. Virus Research. 2021;292:198235.

   DOI10.1016/j.virusres.2020.198235PubMed33232783

3. Larson-Meyer DE, Willis KS. Vitamin D and athletes. Curr Sports Med Rep. 2010;9(4):220-6.

   DOI10.1249/JSR.0b013e3181e7dd45PubMed20622540

4. Dahlquist DT et al. Plausible ergogenic effects of vitamin D on athletic performance and recovery. J Int Soc Sports Nutr. 2015;12(1).

   DOI10.1186/s12970-015-0093-8PubMed26288575

5. Renke G et al. Effects of Vitamin D on Cardiovascular Risk and Oxidative Stress. Nutrients. 2023;15(3):769.

   DOI10.3390/nu15030769PubMed36771474

6. Sassi F et al. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients. 2018;10(11):1656.

   DOI10.3390/nu10111656PubMed30400332

7. Charoenngam N, Holick MF. Immunologic Effects of Vitamin D on Human Health and Disease. Nutrients. 2020;12(7):2097.

   DOI10.3390/nu12072097PubMed32679784

8. Ataide FL et al. Safety and effectiveness of vitamin D mega-dose: A systematic review. Clinical Nutrition ESPEN. 2021;46:115-120.

   DOI10.1016/j.clnesp.2021.09.010PubMed34857184

9. Diamond TH et al. Annual intramuscular injection of a megadose of cholecalciferol for treatment of vitamin D deficiency: efficacy and safety data. Medical Journal of Australia. 2005;183(1):10-12.

   DOI10.5694/j.1326-5377.2005.tb06879.xPubMed15992330

10. Gorman S et al. High-Dose Intramuscular Vitamin D Provides Long-Lasting Moderate Increases in Serum 25-Hydroxvitamin D Levels and Shorter-Term Changes in Plasma Calcium. Journal of AOAC INTERNATIONAL. 2017;100(5):1337-1344.

    DOI10.5740/jaoacint.17-0087PubMed28492140

11. Obeid R et al. Vitamin B12 Intake From Animal Foods, Biomarkers, and Health Aspects. Front. Nutr. 2019;6:93.

    DOI10.3389/fnut.2019.00093PubMed31316992

12. Costa NA et al. Insights Into Thiamine Supplementation in Patients With Septic Shock. Front. Med. 2022;8:805199.

    DOI10.3389/fmed.2021.805199PubMed35155482

13. Sanz-Cuesta T et al. Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12). BMJ Open. 2020;10(8):e033687.

    DOI10.1136/bmjopen-2019-033687PubMed32819927

14. Pardo Lledias J et al. Incidental detection of raised serum levels of vitamin B12 and its association with neoplasms. Revista Clínica Española (English Edition). 2024;224(1):10-16.

    DOI10.1016/j.rceng.2023.12.002PubMed38065526

15. Carr A, Maggini S. Vitamin C and Immune Function. Nutrients. 2017;9(11):1211.

    DOI10.3390/nu9111211PubMed29099763

16. Chen et al., 2008; Hoffer et al., 2008; Padayatty e Levine, 2000; Padayatty et al., 2004; Park et al., 2009.

    Sem DOI ou PMID na referência original.

17. Marik PE. Hydrocortisone, Ascorbic Acid and Thiamine (HAT Therapy) for the Treatment of Sepsis. Focus on Ascorbic Acid. Nutrients. 2018;10(11):1762.

    DOI10.3390/nu10111762PubMed30441816

18. Moretti M et al. Ascorbic Acid to Manage Psychiatric Disorders. CNS Drugs. 2017;31(7):571-583.

    DOI10.1007/s40263-017-0446-8PubMed28600627

19. Patel JJ et al. IV Vitamin C in Critically Ill Patients: A Systematic Review and Meta-Analysis. Critical Care Medicine. 2022;50(3):e304-e312.

    DOI10.1097/CCM.0000000000005320PubMed34637420

20. Brissot P et al. Haemochromatosis. Nat Rev Dis Primers. 2018;4(1):18016.

    DOI10.1038/nrdp.2018.16PubMed29620054

21. Craig WJ. Health effects of vegan diets. Am J Clin Nutr. 2009;89(5):1627S-33S.

    DOI10.3945/ajcn.2009.26736NPubMed19279075

22. Hunt JR. Moving toward a plant-based diet: are iron and zinc at risk? Nutr Rev. 2002;60(5):127-34.

    DOI10.1301/00296640260093788PubMed12030275

23. Institute of Medicine (US) Panel on Micronutrients. National Academies Press (US).

    Sem DOI ou PMID na referência original.

24. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-43.

    DOI10.1056/NEJMra1401038PubMed25946282

25. Cheema B et al. Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency. Journal of the American College of Cardiology. 2024;83(25):2674-2689.

    DOI10.1016/j.jacc.2024.03.431PubMed38897678

26. Aguas-Ayesa M et al. Precision nutrition in the context of bariatric surgery. Rev Endocr Metab Disord. 2023;24(5):979-991.

    DOI10.1007/s11154-023-09794-5PubMed36928810

27. Berger MM et al. ESPEN practical short micronutrient guideline. Clinical Nutrition. 2024;43(3):825-857.

    DOI10.1016/j.clnu.2024.01.030PubMed38350290

28. Dumrongsukit S et al. Nutritional outcomes between different techniques of intradialytic amino acid replacement: a randomized controlled trial. Clinical Kidney Journal. 2025;18(1):sfae361.

    DOI10.1093/ckj/sfae361PubMed40008349

29. Wang J et al. Effect of amino acid supplementation on short-term complications after gastrointestinal tumor surgery: the AMIGITS randomized clinical trial. International Journal of Surgery. 2024;110(12):7806-7815.

    DOI10.1097/JS9.0000000000001818PubMed39051906

Voltar ao índice

1. Rubino F et al. Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology. 2025;13(3):221-262.

   DOI10.1016/S2213-8587(24)00316-4PubMed39824205

2. Michels G, Mattos Rosa G, Renke G, Starling-Soares B, on behalf of SBRAG. Steatosarcopenia: a new terminology for clinical conditions related to body composition classification. Life. 2024;14:1383.

   DOI10.3390/life14111383PubMed39598182

3. Frayling TM et al. Science 2007.

   DOI10.1126/science.1141634PubMed17434869

4. Loos RJF, Yeo GSH. Nat Rev Genetics 2022.

   DOI10.1038/s41576-021-00414-zPubMed34556834

5. De Luis DA et al. Nutrients 2023.

   Sem DOI ou PMID na referência original.

6. Goodarzi MO. Nat Rev Endocrinol 2023.

   Sem DOI ou PMID na referência original.

7. Davies M et al. Diabetes Care 2022.

   DOI10.2337/dci22-0034PubMed36148880

8. Garvey WT et al. Endocrine Practice 2023.

   Sem DOI ou PMID na referência original.

9. Lincoff AM et al. NEJM 2023.

   DOI10.1056/NEJMoa2307563PubMed37952131

10. Drucker DJ. Cell Metabolism 2024.

    Sem DOI ou PMID na referência original.

11. Dolder PC et al. Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects. Front. Pharmacol. 2017;8:617.

    DOI10.3389/fphar.2017.00617PubMed28936175

12. Joseph A et al. Micelle/Hydrogel Composite as a “Natural Self-Emulsifying Reversible Hybrid Hydrogel (N’SERH)” Enhances the Oral Bioavailability of Free (Unconjugated) Resveratrol. ACS Omega. 2022;7(15):12835-12845.

    DOI10.1021/acsomega.2c00116PubMed35474815

13. Mallardo M et al. Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success. Nutrients. 2026;18(17):2748.

    DOI10.3390/nu18172748PubMed42738922

Voltar ao índice